Continuously serving Kosciusko County since 1854
BASEL, Switzerland - Medartis Holding AG, a leading orthopaedic company specializing in head and extremity surgery, reported total sales of CHF 123 million for H1 2025, representing growth of 14.1% at constant exchange rates (CER). Core sales reached CHF 122.1 million with organic growth of 15.3%. EMEA and U.S. operations were key growth drivers, with both regions growing 16%. Following the performance in H1, the Medartis management raises its sales guidance for the full-year.
Matthias Schupp, CEO of Medartis, said, "We delivered on our H1 commitments, giving us confidence in our outlook for the remainder of the year. My focus as CEO over the past nine months has been to strengthen our competitive positioning in the U.S. and LATAM, and to finalize partnerships with NeoOrtho and KeriMedical that will serve as significant growth catalysts beyond 2025. We have also strengthened our R&D team to accelerate internal innovation. The cultural transformation is showing early positive signs - our U.S. team has regained confidence, demonstrating a shift in attitude and adopted a more focused approach, with the new management making difficult yet necessary decisions to create an effective sales channel centered on the Medartis brand.”
Medartis' core business in the U.S. achieved growth of 16.2% (CER) with sales reaching CHF 26.1 million in H1 2025 (PY: CHF 23.2 million), securing additional market share. The declining U.S. contract manufacturing business contributed an additional CHF 1.0 million in sales (PY: CHF 3.9 million). Performance was evenly distributed across product segments.
The comprehensive review of the company's 57 distribution partners and necessary restructuring was completed in H1 2025, resulting in the discontinuation of 20 distributors. Most affected territories have since been reassigned, with the training department actively onboarding new distribution partners. All remaining distributors now operate under exclusive agreements with Medartis.
